288 related articles for article (PubMed ID: 29669721)
1. PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.
Goyal G; Wong K; Nirschl CJ; Souders N; Neuberg D; Anandasabapathy N; Dranoff G
Cancer Immunol Res; 2018 Jun; 6(6):723-732. PubMed ID: 29669721
[TBL] [Abstract][Full Text] [Related]
2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
3. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
4. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. The Activin A-Peroxisome Proliferator-Activated Receptor Gamma Axis Contributes to the Transcriptome of GM-CSF-Conditioned Human Macrophages.
Nieto C; Bragado R; Municio C; Sierra-Filardi E; Alonso B; Escribese MM; Domínguez-Andrés J; Ardavín C; Castrillo A; Vega MA; Puig-Kröger A; Corbí AL
Front Immunol; 2018; 9():31. PubMed ID: 29434585
[TBL] [Abstract][Full Text] [Related]
7. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
8. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
[TBL] [Abstract][Full Text] [Related]
9. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Quezada SA; Peggs KS; Curran MA; Allison JP
J Clin Invest; 2006 Jul; 116(7):1935-45. PubMed ID: 16778987
[TBL] [Abstract][Full Text] [Related]
10. Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during
Rothchild AC; Stowell B; Goyal G; Nunes-Alves C; Yang Q; Papavinasasundaram K; Sassetti CM; Dranoff G; Chen X; Lee J; Behar SM
mBio; 2017 Oct; 8(5):. PubMed ID: 29066547
[TBL] [Abstract][Full Text] [Related]
11. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
He SB; Sun K; Wang L; Li DC; Zhang YY
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
[TBL] [Abstract][Full Text] [Related]
12. Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease.
Schutt CR; Gendelman HE; Mosley RL
Mol Neurodegener; 2018 May; 13(1):26. PubMed ID: 29783988
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in GM-CSF-based cancer immunotherapy.
Yan WL; Shen KY; Tien CY; Chen YA; Liu SJ
Immunotherapy; 2017 Mar; 9(4):347-360. PubMed ID: 28303764
[TBL] [Abstract][Full Text] [Related]
14. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses.
Kim IK; Koh CH; Jeon I; Shin KS; Kang TS; Bae EA; Seo H; Ko HJ; Kim BS; Chung Y; Kang CY
Cancer Immunol Res; 2019 Mar; 7(3):498-509. PubMed ID: 30728152
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
17. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy.
Liang SC; Moskalenko M; Van Roey M; Jooss K
Clin Immunol; 2013 Aug; 148(2):287-98. PubMed ID: 23811319
[TBL] [Abstract][Full Text] [Related]
18. IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy.
Alters SE; Gadea JR; Holm B; Lebkowski J; Philip R
J Immunother; 1999 May; 22(3):229-36. PubMed ID: 10335482
[TBL] [Abstract][Full Text] [Related]
19. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
